Literature DB >> 30606406

Cardiorenal Syndrome in Acute Kidney Injury.

Luca Di Lullo1, Patrick Bronson Reeves2, Antonio Bellasi3, Claudio Ronco4.   

Abstract

Varying degrees of cardiac and kidney dysfunction commonly are observed in hospitalized patients. As a demonstration of the significant interplay between the heart and kidneys, dysfunction or injury of one organ often contributes to dysfunction or injury of the other. The term cardiorenal syndrome (CRS) was proposed to describe this complex organ cross-talk. Type 3 CRS, also known as acute renocardiac syndrome, is a subtype of CRS that occurs when acute kidney injury contributes to or precipitates the development of acute cardiac dysfunction. Acute kidney injury may directly or indirectly produce acute cardiac dysfunction by way of volume overload, metabolic acidosis, electrolyte disorders such as hyperkalemia and hypocalcemia, and other mechanisms. In this review, we examine the definition, epidemiology, pathophysiology, and treatment options for CRS with an emphasis on type 3 CRS.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Acute kidney injury (AKI); cardiorenal syndrome (CRS); diagnosis; pathophysiology; treatment

Mesh:

Year:  2019        PMID: 30606406     DOI: 10.1016/j.semnephrol.2018.10.003

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  8 in total

1.  Incidence and implications of acute kidney injury in patients hospitalized with acute decompensated heart failure.

Authors:  Rajkumar Doshi; Tania Dhawan; Casey Rendon; Marines Acevedo Rodriguez; Jaafar F Al-Khafaji; Mohamed Taha; Thi Thi Win; Nageshwara Gullapalli
Journal:  Intern Emerg Med       Date:  2019-11-04       Impact factor: 3.397

Review 2.  Acute kidney injury.

Authors:  John A Kellum; Paola Romagnani; Gloria Ashuntantang; Claudio Ronco; Alexander Zarbock; Hans-Joachim Anders
Journal:  Nat Rev Dis Primers       Date:  2021-07-15       Impact factor: 52.329

3.  Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway.

Authors:  Jin Wang; Xuefeng Sun; Xu Wang; Shaoyuan Cui; Ran Liu; Jiaona Liu; Bo Fu; Ming Gong; Conghui Wang; Yushen Shi; Qianqian Chen; Guangyan Cai; Xiangmei Chen
Journal:  Front Cell Dev Biol       Date:  2021-03-22

4.  Mitochondrial Dysfunction in Cardiorenal Syndrome 3: Renocardiac Effect of Vitamin C.

Authors:  Raquel Silva Neres-Santos; Carolina Victoria Cruz Junho; Karine Panico; Wellington Caio-Silva; Joana Claudio Pieretti; Juliana Almeida Tamashiro; Amedea Barozzi Seabra; César Augusto João Ribeiro; Marcela Sorelli Carneiro-Ramos
Journal:  Cells       Date:  2021-11-05       Impact factor: 6.600

Review 5.  Cardiorenal Syndrome: New Pathways and Novel Biomarkers.

Authors:  Guido Gembillo; Luca Visconti; Maria Ausilia Giusti; Rossella Siligato; Alessia Gallo; Domenico Santoro; Alessandro Mattina
Journal:  Biomolecules       Date:  2021-10-26

6.  Influence of Red Blood Cell Distribution Width on All-Cause Death in Critical Diabetic Patients with Acute Kidney Injury.

Authors:  Yunhua Liao; Zhenhua Yang; Manqiu Mo; Zichun Huang; Dongmei Huo; Ling Pan; Ning Xia
Journal:  Diabetes Metab Syndr Obes       Date:  2022-08-02       Impact factor: 3.249

7.  Characterization of the Oxidative Stress in Renal Ischemia/Reperfusion-Induced Cardiorenal Syndrome Type 3.

Authors:  Wellington Caio-Silva; Danielle da Silva Dias; Carolina Victoria Cruz Junho; Karine Panico; Raquel Silva Neres-Santos; Milena Trevisan Pelegrino; Joana Claudio Pieretti; Amedea Barozzi Seabra; Kátia De Angelis; Marcela Sorelli Carneiro-Ramos
Journal:  Biomed Res Int       Date:  2020-10-09       Impact factor: 3.411

Review 8.  Anticipating the long-term cardiovascular effects of COVID-19.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2020-10       Impact factor: 2.300

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.